Pteroic acid
Based on 1 publication(s) in Google Scholar
Pteroic acid is a precursor to significant compounds like Folic acid (HY-16637) and Vitamin B12 (HY-B0315). Pteroic acid facilitates the examination of how different compounds influence cell growth and development.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.05%
- CAS No.: 119-24-4
- 화학식: C14H12N6O3
- 분자량:312.29
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pteroic acid
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
16 μM
Compound: 12
|
Inhibitory activity against CDK4 using recombinant human cyclin D2-CDK4 complex expressed in sf9 cells
Inhibitory activity against CDK4 using recombinant human cyclin D2-CDK4 complex expressed in sf9 cells
|
[PMID: 11741479] |
Pteroic acid (100-200 μM; 2 h) stimulates partially purified beef liver folylpolyglutamate synthetase (FPGS) activity by strengthening the binding of pteridine substrates (without altering glutamate binding)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 119-24-4
-
Appearance Solid
-
분자량 312.29
-
화학식 C14H12N6O3
-
Color Yellow to brown
-
SMILES
OC(C1=CC=C(NCC2=NC3=C(N=C2)N=C(N)NC3=O)C=C1)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
ACS Omega
2025 Jul 2;10(27):29224-29240. PMID: 40687049
용액&용해도
0.5 M NaOH : 50 mg/mL (160.11 mM; adjust pH to 12 with H2O)
DMSO : 5.6 mg/mL (17.93 mM; ultrasonic and warming and adjust pH to 11 with 1 M NaOH and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.62 mg/mL (1.99 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.62 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.62 mg/mL (1.99 mM); Clear solution
This protocol yields a clear solution of ≥ 0.62 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Vickers PJ, et al. Activation of folypolyglutamate synthetase by pteroic acid. Can J Biochem Cell Biol. 1985 Jul;63(7):777-9. [Content Brief]
[2]. Ke CY, et al. Targeting the tumor-associated folate receptor with an 111In-DTPA conjugate of pteroic acid. J Am Chem Soc. 2005;127(20):7421-7426. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.5 M NaOH | 1 mM | 3.2022 mL | 16.0108 mL | 32.0215 mL | 80.0538 mL |
| 5 mM | 0.6404 mL | 3.2022 mL | 6.4043 mL | 16.0108 mL | |
| 10 mM | 0.3202 mL | 1.6011 mL | 3.2022 mL | 8.0054 mL | |
| 15 mM | 0.2135 mL | 1.0674 mL | 2.1348 mL | 5.3369 mL | |
| 0.5 M NaOH | 20 mM | 0.1601 mL | 0.8005 mL | 1.6011 mL | 4.0027 mL |
| 25 mM | 0.1281 mL | 0.6404 mL | 1.2809 mL | 3.2022 mL | |
| 30 mM | 0.1067 mL | 0.5337 mL | 1.0674 mL | 2.6685 mL | |
| 40 mM | 0.0801 mL | 0.4003 mL | 0.8005 mL | 2.0013 mL | |
| 50 mM | 0.0640 mL | 0.3202 mL | 0.6404 mL | 1.6011 mL | |
| 60 mM | 0.0534 mL | 0.2668 mL | 0.5337 mL | 1.3342 mL | |
| 80 mM | 0.0400 mL | 0.2001 mL | 0.4003 mL | 1.0007 mL | |
| 100 mM | 0.0320 mL | 0.1601 mL | 0.3202 mL | 0.8005 mL |
Pteroic acid Related Classifications
HY-79139 Related Classifications
Powered by Bioz